scholarly journals Recent progress in mucosal vaccine development: potential and limitations

2012 ◽  
Vol 12 (8) ◽  
pp. 592-605 ◽  
Author(s):  
Nils Lycke
Keyword(s):  
Recent Progress ◽  
Vaccine Development ◽  
Mucosal Vaccine ◽  
Development Potential

scholarly journals Mucosal Vaccine Development Based on Liposome Technology

2016 ◽  
Vol 2016 ◽  
pp. 1-16 ◽  
Author(s):  
Valentina Bernasconi ◽  
Karin Norling ◽  
Marta Bally ◽  
Fredrik Höök ◽  
Nils Y. Lycke
Keyword(s):  
Immune Responses ◽  
Protective Immunity ◽  
Recent Progress ◽  
Vaccine Development ◽  
Mucosal Vaccine ◽  
Limiting Factor ◽  
Successful Development ◽  
Mucosal Vaccines ◽  
Increasing Demand ◽  
Portal Of Entry

Immune protection against infectious diseases is most effective if located at the portal of entry of the pathogen. Hence, there is an increasing demand for vaccine formulations that can induce strong protective immunity following oral, respiratory, or genital tract administration. At present, only few mucosal vaccines are found on the market, but recent technological advancements and a better understanding of the principles that govern priming of mucosal immune responses have contributed to a more optimistic view on the future of mucosal vaccines. Compared to live attenuated vaccines, subcomponent vaccines, most often protein-based, are considered safer, more stable, and less complicated to manufacture, but they require the addition of nontoxic and clinically safe adjuvants to be effective. In addition, another limiting factor is the large antigen dose that usually is required for mucosal vaccines. Therefore, the combination of mucosal adjuvants with the recent progress in nanoparticle technology provides an attractive solution to these problems. In particular, the liposome technology is ideal for combining protein antigen and adjuvant into an effective mucosal vaccine. Here, we describe and discuss recent progress in nanoparticle formulations using various types of liposomes that convey strong promise for the successful development of the next generation of mucosal vaccines.

Mucosal vaccine development for botulinum intoxication

2007 ◽  
Vol 6 (1) ◽  
pp. 35-45 ◽  
Author(s):  
Kohtaro Fujihashi ◽  
Herman F Staats ◽  
Shunji Kozaki ◽  
David W Pascual
Keyword(s):  
Vaccine Development ◽  
Mucosal Vaccine

Recent progress in tumour vaccine development

2003 ◽  
Vol 12 (6) ◽  
pp. 971-981 ◽  
Author(s):  
I Caroline Le Poole ◽  
Hemamalini Bommiasamy ◽  
W Martin Kast
Keyword(s):  
Recent Progress ◽  
Vaccine Development ◽  
Tumour Vaccine

scholarly journals Approaches to Tuberculosis Mucosal Vaccine Development Using Nanoparticles and Microparticles: A Review

2014 ◽  
Vol 10 (9) ◽  
pp. 2295-2316 ◽  
Author(s):  
Liliana Aranha Caetano ◽  
António José Almeida ◽  
Lídia Maria Diogo Gonçalves
Keyword(s):  
Vaccine Development ◽  
Mucosal Vaccine

scholarly journals Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV

Viruses ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1871
Author(s):  
Naglaa H. Shoukry
Keyword(s):  
Systems Biology ◽  
Protective Immunity ◽  
Recent Progress ◽  
Viral Infections ◽  
Vaccine Development ◽  
Immune Functions ◽  
The Past ◽  
Systems Immunology ◽  
Tremendous Progress ◽  
Made In

Over the past decade, tremendous progress has been made in systems biology-based approaches to studying immunity to viral infections and responses to vaccines. These approaches that integrate multiple facets of the immune response, including transcriptomics, serology and immune functions, are now being applied to understand correlates of protective immunity against hepatitis C virus (HCV) infection and to inform vaccine development. This review focuses on recent progress in understanding immunity to HCV using systems biology, specifically transcriptomic and epigenetic studies. It also examines proposed strategies moving forward towards an integrated systems immunology approach for predicting and evaluating the efficacy of the next generation of HCV vaccines.

scholarly journals Intranasal Vaccination With Recombinant Antigen-FLIPr Fusion Protein Alone Induces Long-Lasting Systemic Antibody Responses and Broad T Cell Responses

2021 ◽  
Vol 12 ◽  
Author(s):  
Ming-Shu Hsieh ◽  
Chia-Wei Hsu ◽  
Ling-Ling Tu ◽  
Kit Man Chai ◽  
Li-Lu Yu ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Zika Virus ◽  
Intranasal Administration ◽  
Vaccine Development ◽  
Protein Domain ◽  
Mucosal Vaccine ◽  
Formyl Peptide Receptor ◽  
Infection Model ◽  
Virus Envelope ◽  
Iga Antibodies

A simple formulation is urgently needed for mucosal vaccine development. We employed formyl peptide receptor-like 1 inhibitory protein (FLIPr), an FcγR antagonist secreted by Staphylococcus aureus, as a vector to target ovalbumin (OVA) to dendritic cells (DCs) via intranasal administration. Our results demonstrate that intranasal administration of recombinant OVA-FLIPr fusion protein (rOVA-FLIPr) alone efficiently delivers OVA to DCs in nasal lymphoid tissue. Subsequently, OVA-specific IgG and IgA antibodies in the circulatory system and IgA antibodies in mucosal tissue were detected. Importantly, activation of OVA-specific CD4+ and CD8+ T cells and induction of a broad-spectrum cytokine secretion profile were detected after intranasal administration of rOVA-FLIPr alone in immunocompetent C57BL/6 mice. Furthermore, we employed immunodeficient AG129 mice as a Zika virus infection model and demonstrated that intranasal administration of recombinant Zika virus envelope protein domain III-FLIPr fusion protein induced protective immune responses against the Zika virus. These results suggest that antigen-FLIPr fusion protein alone via intranasal administration can be applied to mucosal vaccine development.

Sign in / Sign up

Export Citation Format

Share Document